Objectif
Many tumor cells are characterized by the overexpression of certain antigens. Molecules that specifically recognize these structures are suitable as homing devices in tumor therapy. Conjugates of anticancer drugs with such a delivery vector targeting tumors would be a “magic bullet” according to the Nobel laureate Paul Ehrlich. Three antibody-drug conjugates (ADC) have already been approved for anticancer therapy. However, ADC have e.g. limitations with respect to tumor penetration, high manufacturing costs, and require challenging conjugation chemistry. Peptide-drug conjugates can have a high drug loading, easily penetrate tissue, and can be easily prepared in a homogenous form with straightforward and well-defined conjugation chemistry.
The ETN MAGICBULLET will focus on chemistry-driven approaches toward conjugates between peptides (delivery vectors) that recognize tumors and anticancer drugs (payloads or warheads) in order to selectively fight cancer, a topic with a high demand of research activities. The ETN will develop and validate an array of new peptide-drug conjugates combining either known tumor-specific peptides or newly discovered tumor-homing peptides with potent cytotoxic drugs. The tumor-selective peptides are designed for cellular uptake mediated either by endocytosis or by cell-penetrating peptides. The consortium of the ETN MAGICBULLET covers tumor biology, biochemistry, pharmacology, synthetic chemistry, medicinal chemistry, spectroscopy, conformational analysis, and computational chemistry.
The training program focuses on multidisciplinary research to explore and validate molecular targets for innovative treatment or investigations on the molecular mechanisms in organ-specific metastatic growth processes. It aims at scientific multilingualism and relies e.g. on concerted learning, a combination of introductory training, hands-on learning “on the bench”, teaching by peers, and training in additional skills.
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesbasic medicinemedicinal chemistry
- natural sciencesbiological sciencescell biology
- medical and health sciencesclinical medicineoncologycolorectal cancer
- medical and health sciencesbasic medicinetoxicology
Programme(s)
Régime de financement
MSCA-ITN-ETN - European Training NetworksCoordinateur
33615 Bielefeld
Allemagne
Voir sur la carte
Participants (8)
21100 Varese
Voir sur la carte
1053 Budapest
Voir sur la carte
00014 Helsingin Yliopisto
Voir sur la carte
20122 Milano
Voir sur la carte
50931 Koln
Voir sur la carte
1122 Budapest
Voir sur la carte
68526 Ladenburg
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
00182 Roma
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
Partenaires (5)
Les organisations partenaires contribuent à la mise en œuvre de l’action, mais ne signent pas la convention de subvention.
13353 Berlin
Voir sur la carte
Les organisations partenaires contribuent à la mise en œuvre de l’action, mais ne signent pas la convention de subvention.
91054 Erlangen
Voir sur la carte
Les organisations partenaires contribuent à la mise en œuvre de l’action, mais ne signent pas la convention de subvention.
1032 Budapest
Voir sur la carte
Les organisations partenaires contribuent à la mise en œuvre de l’action, mais ne signent pas la convention de subvention.
80686 Munchen
Voir sur la carte
Les organisations partenaires contribuent à la mise en œuvre de l’action, mais ne signent pas la convention de subvention.
00040 Pomezia Rm
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.